4.8 Article

A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression

Journal

NATURE COMMUNICATIONS
Volume 9, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41467-018-02851-7

Keywords

-

Funding

  1. SINF
  2. MDACC grant
  3. NIH Skin Cancer SPORE [P50 CA 093459]
  4. NCI [P50 CA140388]
  5. NIH Clinical Research Loan Repayment Program
  6. National Institutes of Health (NIH/NCATS) [UH3TR00943]
  7. NIH/NCI [R01-CA182905]
  8. UT MD Anderson Cancer Center SPORE in Melanoma grant from NIH/NCI [P50 CA093459]
  9. AIM at Melanoma Foundation
  10. Miriam Mulva research fund
  11. Jim Mulva research fund
  12. CLL Moonshot Flagship project

Ask authors/readers for more resources

Previously we have reported that metastatic melanoma cell lines and tumor specimens have reduced expression of ADAR1 and consequently are impaired in their ability to perform A-to-I microRNA (miRNA) editing. The effects of A-to-I miRNAs editing on melanoma growth and metastasis are yet to be determined. Here we report that miR-378a-3p is undergoing A-to-I editing only in the non-metastatic but not in metastatic melanoma cells. The function of the edited form is different from its wild-type counterpart. The edited form of miR-378a-3p preferentially binds to the 3'-UTR of the PARVA oncogene and inhibits its expression, thus preventing the progression of melanoma towards the malignant phenotype. Indeed, edited miR-378a-3p but not its WT form inhibits melanoma metastasis in vivo. These results further emphasize the role of RNA editing in melanoma progression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available